Advantages of pure platelet-rich plasma compared with leukocyte- and platelet-rich plasma in treating rabbit knee osteoarthritis

Medical Science Monitor

Volumn 22, Issue , 2016, Pages 1280-1290

  Yin, Wen Jing ^a   Xu, Hai Tao ^a   Sheng, Jia Gen ^a   An, Zhi Quan ^a   Guo, Shang Chun ^a   Xie, Xue Tao ^a   Zhang, Chang Qing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Cytokines; Leukocytes; NF kappa B; Osteoarthritis; Platelet rich plasma; Rabbits

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARTILAGE DEGENERATION; CARTILAGE MATRIX; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; INFLAMMATION; KNEE OSTEOARTHRITIS; LEUKOCYTE; LEUKOCYTE AND PLATELET RICH PLASMA; MALE; NONHUMAN; PLASMA; RABBIT; SYNOVIAL FLUID; THROMBOCYTE RICH PLASMA; TREATMENT OUTCOME; ANIMAL; BLOOD; LEUKOCYTE TRANSFUSION; METABOLISM; OSTEOARTHRITIS, KNEE; PROCEDURES; RABBITS AND HARES; RANDOMIZATION; THROMBOCYTE TRANSFUSION;

ANIMALS; CYTOKINES; DINOPROSTONE; FEMALE; INTERLEUKIN-1BETA; LEUKOCYTE TRANSFUSION; NF-KAPPA B; OSTEOARTHRITIS, KNEE; PLATELET TRANSFUSION; PLATELET-RICH PLASMA; RABBITS; RANDOM ALLOCATION; SYNOVIAL FLUID;

EID: 84964307387     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.898218     Document Type: Article

References (54)

1. Woolf AD, Pfleger B: Burden of major musculoskeletal conditions. Bull World Health Organ, 2003; 81: 646–56
2. Santaguida PL, Hawker GA, Hudak PL et al: Patient characteristics affecting the prognosis of total hip and knee joint arthroplasty: A systematic review. Can J Surg, 2008; 51: 428–36
3. Muir H: The chondrocyte, architect of cartilage. Biomechanics, structure, function and molecular biology of cartilage matrix macromolecules. Bioessays, 1995; 17: 1039–48.
4. Chevalier X, Eymard F, Richette P: Biologic agents in osteoarthritis: Hopes and disappointments. Nat Rev Rheumatol, 2013; 9: 400–10
5. Castillo TN, Pouliot MA, Kim HJ, Dragoo JL: Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med, 2011; 39: 266–71
6. Magalon J, Bausset O, Serratrice N et al: Characterization and comparison of 5 platelet-rich plasma preparations in a single-donor model. Arthroscopy, 2014; 30: 629–38
7. Appel TR, Potzsch B, Muller J et al: Comparison of three different preparations of platelet concentrates for growth factor enrichment. Clin Oral Implants Res, 2002; 13: 522–28
8. Ellman MB, An HS, Muddasani P, Im HJ: Biological impact of the fibroblast growth factor family on articular cartilage and intervertebral disc homeostasis. Gene, 2008; 420: 82–89
9. Brandl A, Angele P, Roll C et al: Influence of the growth factors PDGF-BB, TGF-beta1 and bFGF on the replicative aging of human articular chondrocytes during in vitro expansion. J Orthop Res, 2010; 28: 354–60
10. Fortier LA, Barker JU, Strauss EJ et al: The role of growth factors in cartilage repair. Clin Orthop Relat Res, 2011; 469: 2706–15.
11. Kon E, Mandelbaum B, Buda R et al: Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: From early degeneration to osteoarthritis. Arthroscopy, 2011; 27: 1490–501.
12. Filardo G, Kon E, Buda R et al: Platelet-rich plasma intra-articular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. Knee Surg Sports Traumatol Arthrosc, 2011; 19: 528–35.
13. Kon E, Buda R, Filardo G et al: Platelet-rich plasma: intra-articular knee injections produced favorable results on degenerative cartilage lesions. Knee Surg Sports Traumatol Arthrosc, 2010; 18: 472–79.
14. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T: Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol, 2009; 27: 158–67.
15. Sundman EA, Cole BJ, Fortier LA: Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med, 2011; 39: 2135–40.
16. Burguera EF, Vela-Anero A, Magalhaes J et al: Effect of hydrogen sulfide sources on inflammation and catabolic markers on interleukin 1beta-stimulated human articular chondrocytes. Osteoarthritis Cartilage, 2014; 22: 1026–35.
17. Campbell KA, Minashima T, Zhang Y et al: Annexin A6 interacts with p65 and stimulates NF-kappaB activity and catabolic events in articular chondrocytes. Arthritis Rheum, 2013; 65: 3120–29.
18. Davidson RK, Jupp O, de Ferrars R et al: Sulforaphane represses matrix-degrading proteases and protects cartilage from destruction in vitro and in vivo. Arthritis Rheum, 2013; 65: 3130–40.
19. Cavallo C, Filardo G, Mariani E et al: Comparison of platelet-rich plasma formulations for cartilage healing: An in vitro study. J Bone Joint Surg Am, 2014; 96: 423–29.
20. Yoshioka M, Coutts RD, Amiel D, Hacker SA: Characterization of a model of osteoarthritis in the rabbit knee. Osteoarthritis Cartilage, 1996; 4: 87–98.
21. Sanchez M, Anitua E, Azofra J et al: Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee OA: A retrospective cohort study. Clin Exp Rheumatol, 2008; 26: 910–13.
22. Napolitano M, Matera S, Bossio M et al: Autologous platelet gel for tissue regeneration in degenerative disorders of the knee. Blood Transfus, 2012; 10: 72–77.
23. Spakova T, Rosocha J, Lacko M et al: Treatment of knee joint osteoarthritis with autologous platelet-rich plasma in comparison with hyaluronic acid. Am J Phys Med Rehabil, 2012; 91: 411–17.
24. Sanchez M, Fiz N, Azofra J et al: A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the shortterm treatment of symptomatic knee osteoarthritis. Arthroscopy, 2012; 28: 1070–78.
25. Altug ME, Serarslan Y, Bal R et al: Caffeic acid phenethyl ester protects rabbit brains against permanent focal ischemia by antioxidant action: A biochemical and planimetric study. Brain Res, 2008; 1201: 135–42.
26. Jia WT, Zhang CQ, Wang JQ et al: The prophylactic effects of platelet-leucocyte gel in osteomyelitis: An experimental study in a rabbit model. J Bone Joint Surg Br, 2010; 92: 304–10.
27. Amiel D, Toyoguchi T, Kobayashi K et al: Long-term effect of sodium hyaluronate (Hyalgan) on osteoarthritis progression in a rabbit model. Osteoarthritis Cartilage, 2003; 11: 636–43.
28. Batten ML, Hansen JC, Dahners LE: Influence of dosage and timing of application of platelet-derived growth factor on early healing of the rat medial collateral ligament. J Orthop Res, 1996; 14: 736–41.
29. Torricelli P, Fini M, Filardo G et al: Regenerative medicine for the treatment of musculoskeletal overuse injuries in competition horses. Int Orthop, 2011; 35: 1569–76.
30. Weibrich G, Hansen T, Kleis W et al: Effect of platelet concentration in platelet- rich plasma on peri-implant bone regeneration. Bone, 2004; 34: 665–71.
31. Anitua E, Sanchez M, Zalduendo MM et al: Fibroblastic response to treatment with different preparations rich in growth factors. Cell Prolif, 2009; 42: 162–70.
32. Heldin CH, Eriksson U, Ostman A: New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys, 2002; 398: 284–90.
33. Yaeger PC, Masi TL, de Ortiz JL et al: Synergistic action of transforming growth factor-beta and insulin-like growth factor-I induces expression of type II collagen and aggrecan genes in adult human articular chondrocytes. Exp Cell Res, 1997; 237: 318–25.
34. Stewart K, Pabbruwe M, Dickinson S et al: The effect of growth factor treatment on meniscal chondrocyte proliferation and differentiation on polyglycolic acid scaffolds. Tissue Eng, 2007; 13: 271–80.
35. Redini F, Mauviel A, Pronost S et al: Transforming growth factor beta exerts opposite effects from interleukin-1 beta on cultured rabbit articular chondrocytes through reduction of interleukin-1 receptor expression. Arthritis Rheum, 1993; 36: 44–50.
36. Berg U, Gustafsson T, Sundberg CJ et al: Local changes in the insulin-like growth factor system in human skeletal muscle assessed by microdialysis and arterio-venous differences technique. Growth Horm IGF Res, 2006; 16: 217–23.
37. Novak ML, Koh TJ: Macrophage phenotypes during tissue repair. J Leukoc Biol, 2013; 93: 875–81.
38. Li H, Hicks JJ, Wang L et al: Customized platelet-rich plasma with transforming growth factor beta1 neutralization antibody to reduce fibrosis in skeletal muscle. Biomaterials, 2016; 87: 147–56.
39. Bielecki T, Dohan Ehrenfest DM et al: The role of leukocytes from L-PRP/LPRF in wound healing and immune defense: New perspectives. Curr Pharm Biotechnol, 2012; 13: 1153–62.
40. Murray PJ, Wynn TA: Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol, 2011; 11: 723–37.
41. Russell RP, Apostolakos J, Hirose T et al: Variability of platelet-rich plasma preparations. Sports Med Arthrosc, 2013; 21: 186–90.
42. McCarrel TM, Minas T, Fortier LA: Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. J Bone Joint Surg Am, 2012; 94: e143(1–8).
43. Wood DD, Ihrie EJ, Dinarello CA, Cohen PL: Isolation of an interleukin-1-like factor from human joint effusions. Arthritis Rheum, 1983; 26: 975–83.
44. Saklatvala J: Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature, 1986; 322: 547–49.
45. Pujol JP, Chadjichristos C, Legendre F et al: Interleukin-1 and transforming growth factor-beta 1 as crucial factors in osteoarthritic cartilage metabolism. Connect Tissue Res, 2008; 49: 293–97.
46. Liu Y, Peng H, Meng Z, Wei M: Correlation of IL-17 level in synovia and severity of knee osteoarthritis. Med Sci Monit, 2015; 21: 1732–36.
47. Henderson B, Pettipher ER: Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: Evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol, 1989; 75: 306–10.
48. Bacconnier L, Jorgensen C, Fabre S: Erosive osteoarthritis of the hand: Clinical experience with anakinra. Ann Rheum Dis, 2009; 68: 1078–79.
49. Grunke M, Schulze-Koops H: Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade. Ann Rheum Dis, 2006; 65: 555–56.
50. Ou Y, Tan C, An H et al: Selective COX-2 inhibitor ameliorates osteoarthritis by repressing apoptosis of chondrocyte. Med Sci Monit, 2012; 18(6): BR247– BR52.
51. Pereira RC, Scaranari M, Benelli R et al: Dual effect of platelet lysate on human articular cartilage: A maintenance of chondrogenic potential and a transient proinflammatory activity followed by an inflammation resolution. Tissue Eng Part A, 2013; 19: 1476–88
52. van Buul GM, Koevoet WL, Kops N et al: Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes. Am J Sports Med, 2011; 39: 2362–70.
53. Ledoux AC, Perkins ND: NF-kappaB and the cell cycle. Biochem Soc Trans, 2014; 42: 76–81.
54. Marcu KB, Otero M, Olivotto E et al: NF-ΚB signaling: multiple angles to target OA. Curr Drug Targets, 2010; 11: 599–613